Altimmune Inc. (NASDAQ:ALT) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET

Company Participants

Vipin Garg - President, Chief Executive Officer

Richard Eisenstadt - Chief Financial Officer

Scott Harris - Chief Medical Officer

Scot Roberts - Chief Scientific Officer

Conference Call Participants

Seamus Fernandez - Guggenheim Securities

Yasmeen Rahimi - Piper Sandler

Roger Song - Jefferies

Corrine Jenkins - Goldman Sachs

Mayank Mamtani - B. Riley

Jon Wolleben - JMP Securities

Joe Pantginis - HC Wainwright

Operator

Good day ladies and gentlemen, and welcome to the Altimmune Inc. full year and fourth quarter 2022 financial results conference call.

At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session and instructions will follow at that time. To ask a question during this session, you will need to press star-one-one on your telephone. As a reminder, this call is being recorded.

I would now like to introduce your host for today’s conference call, Rich Eisenstadt, Chief Financial Officer of Altimmune. Rich, you may begin.

Richard Eisenstadt

Thank you Gigi, and good morning everyone. Thank you for participating in Altimmune’s full year and fourth quarter 2022 financial results and business update conference call.

Members of Altimmune team joining me on the call today are Vipin Garg, our Chief Executive Officer, Scot Roberts, our Chief Scientific Officer, and Scott Harris, our Chief Medical Officer. Following the prepared remarks, we will hold a question and answer session.

A press release with our full year and fourth quarter 2022 financial results was issued this morning and can be found on the Investor Relations section of the company’s website.

Before we begin, I would like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for purposes of Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For a discussion of some of the risks and factors that could affect the company’s future results and operations, please see the Risk Factors and other cautionary statements contained in the company’s filings with the SEC.

I would also direct you to read the forward-looking statements disclaimer in our press release issued this morning and now available on our website. Any statements made on this conference call speak only as of today’s date, Tuesday, February 28, 2023, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today’s date.